Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio.
Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio.
Cancer Res Commun. 2023 Sep 22;3(9):1917-1926. doi: 10.1158/2767-9764.CRC-23-0233.
Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population. Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use. Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use. This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.
Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.
疼痛、恶心和焦虑等症状在癌症患者中很常见。这些问题的治疗通常具有挑战性。大麻产品可能有助于减轻这些症状的严重程度。虽然一些研究包括癌症患者大麻使用的患病率数据，但详细数据仍然有限，并且没有报告在该人群中使用大麻二酚 (CBD) 的患病率。在一家大型 NCI 指定的综合癌症中心的 8 个诊所就诊的成年癌症患者在 2021 年至 2022 年间完成了一份详细的、以大麻为重点的问卷。合格的参与者被诊断患有侵袭性癌症，并在过去 12 个月内接受治疗。总结统计数据用于描述样本中关于大麻使用的情况。大约 15%（n = 142）同意参与的患者（n = 934）报告了当前的大麻使用（定义为在过去 12 个月内使用）。其中，75%的人在过去一周内使用了大麻。在当前的大麻使用者中，39%（n = 56；占 6%）使用 CBD 产品。当前使用者报告每周平均使用大麻 4.5 天（四分位距：0.6-7.0），每天使用 2.0 次（1.0-3.0），使用年限为 3 年（0.8-30.0）。使用模式因给药途径而异。患者报告使用大麻后症状有中度至高度缓解。就大麻测量而言，这项研究是迄今为止最详细的，提供了关于当前活跃癌症中大麻使用情况的信息。未来的研究应包括对大麻产品使用的完整评估、多个招募地点和多样化的患者群体。
临床医生应该意识到患者正在使用大麻产品，并认为使用大麻可以缓解症状。
